Novel therapeutic approaches and drug-delivery technologies are improving control of pain and inflammation after cataract and other ocular surgeries.
Preventing floppy iris syndrome
Phenylephrine and ketorolac intraocular solution 1%/0.3% (Omidria, Omeros) was FDA approved in 2014 and is indicated for maintaining pupil size and preventing intraoperative miosis during cataract surgery and reducing postoperative ocular pain.
This drug added to the irrigating solution during cataract surgery is particularly beneficial in patients who may have used alpha-blockers such as tamsulosin hydrochloride (Flomax, Sanofi) or other alpha blockers and are at possible risk of iris prolapse or billowing, also known as intraoperative floppy iris syndrome.
“Both Dextenza and Dexycu now have a permanent reimbursement J code,” she said.
Alice Epitropoulos, MD
E: [email protected]
Dr. Epitropoulos is a speaker and/or consultant for Bausch + Lomb, EyePoint Pharmaceuticals, Kala Pharmaceuticals, Ocular Therapeutix, and Omeros.